The pharmaceutical industry and health policy

Torbett, Richard; Han, Donald; Bagchi, Indranil

doi:10.1002/9781118949740.ch22

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, the study of monoclonal antibodies as new therapeutic approaches has attracted considerable attention of the pharmaceutical industry, and these product innovations have been a considerable economic success [45]. For example, the utilization of the anti-TNF alpha medicines for use in rheumatoid arthritis has also grown appreciably in recent years in view of their effectiveness especially once concerns with their safety in routine clinical care had been addresses through registries [6]- [46]- [47]- [48]- [49].…”

Section: Typologymentioning

confidence: 99%

“…According to Becker and Lillemark [73] within pharmaceutical industry, the development of new medicines through R&D is common, which still persists today [6]- [74], combined with the delivery of these products to the market. Typically, marketing departments have considerable budgets in comparison to other departments [75], enhancing the profitability of the sector [76].…”

Section: Typologymentioning

confidence: 99%

“…Sildenafil provided intense displacement with significant substitution of the previous drug, as well as creating new clients who started treatment due to the ease of oral therapy. Monoclonal antibodies are another example [6]- [43]- [44]- [45]- [46]- [47]-DOI: 10.18535/ijsrm/v5i7.20 [48]- [49]. The selective serotonin re-uptake inhibitors (SSRIs) launched in 1987 are also an example as they helped to revolutionize the management of depression in ambulatory care [99].…”

Section: -[96]-[97] H2 Antagonists Appreciably Reducing the Need For ...mentioning

confidence: 99%

“…This importance stems from the joint responsibility with the medical profession for the maintenance of health, which, in itself, is already a valuable asset, as well as enhancing productivity. This is expected to continue with the discovery and development of new medicines to treat areas of unmet need [5]- [6]. In addition, innovations are essential for the continued success of pharmaceutical companies with the increasing availability of standard medicines as low cost generics and biosimilars [7] although this can be hard to achieve [8]- [9].…”

Section: Introduction and Theorical Frameworkmentioning

confidence: 99%

See 3 more Smart Citations

A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry

Prata

Silvestre

Godman

et al. 2017

int.jour.sci.res.mana

View full text Add to dashboard Cite

Background: The pharmaceutical sector undertakes extensive research and development (R&D). Pharmaceutical industries have continued to launch an appreciable number of new medicines, different pharmaceutical formulations, new indications and other innovations that contribute to the growth of this sector. New novel medicines are increasingly essential for continued success given the number of standard medicines now available as low cost generics or biosimilars. Consequently, innovation is a fundamental element in pharmaceutical company competition. Not all innovations though are the same size, type or category with differentiation of innovation essential for commercial success. However, given the wide range of definitions used in the literature, the framing may diffuse. Currently, there are several types and categories of innovation are deficiently harmonized and poorly stratified resulting in analysis trends and provide major obstacles to innovation’s differentiation and in assessing the company's innovative dominant characteristic in the sector. The objective of this study is to stratify and organize, didactically, the field of definitions and concepts of innovation and provide a structural and operational delineation, from a critical point of view, for the classifications of innovation applied to the pharmaceutical industry.

show abstract